Journal of Clinical Epidemiology
Volume 57, Issue 12 , Pages 1279-1287 , December 2004

Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated

  • Gordon Guyatt

      Affiliations

    • Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    • Department of Medicine, HSC-2C12, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada
    • Corresponding Author InformationCorresponding author. Tel.: 905-525-9140, ext.22900; fax: 905-524-3841.
    • ,
  • Bruce Weaver

      Affiliations

    • Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    • ,
  • Lisa Cronin

      Affiliations

    • Department of Medicine, HSC-2C12, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada
    • ,
  • Julie Ann Dooley

      Affiliations

    • Pfizer Limited, Tadworth, Surrey, UK
    • ,
  • Ricardo Azziz

      Affiliations

    • Departments of Obstetrics and Gynecology, and Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

,Accepted 16 October 2003.

References 

  1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078–3082
  2. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434–2438
  3. Hull MGR. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol. 1987;1:235–245
  4. Franks S. Polycystic ovary syndrome. [Erratum in: N Engl J Med 1995;333:1435.] N Engl J Med. 1995;333:853–861
  5. Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol (Oxf). 1989;30:459–470
  6. Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?. Am J Obstet Gynecol. 1992;167:1807–1812
  7. Sonino N, Fava GA, Mani E, Belluardo P, Boscaro M. Quality of life of hirsute women. Postgrad Med J. 1993;69:186–189
  8. Paulson JD, Haarmann BS, Salerno RL, Asmar P. An investigation of the relationship between emotional maladjustment and infertility. Fertil Steril. 1988;49:258–262
  9. Downey J, Yingling S, McKinney M, Husami N, Jewelewicz R, Maidman J. Mood disorders, psychiatric symptoms, and distress in women presenting for infertility evaluation. Fertil Steril. 1989;2:425–432
  10. Grieco A, Long CJ. Investigation of the Karnofsky Performance Status as a measure of quality of life. Health Psychol. 1984;3:129–142
  11. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of health status measure. Med Care. 1981;19:787–805
  12. Andrews FM, Withey SB. Social indicators of well-being: Americans' perception of life quality. New York: Plenum Press; 1976;
  13. Morrow GR, Chiarello RJ, Derogatis LR. A new scale for assessing patients' psychosocial adjustment to medical illness. Psychol Med. 1978;8:605–610
  14. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305:160–164
  15. Ware JE, Sherbourne CD. The MOS 36 Item Short-Form Health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483
  16. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. 1993;306:1437–1440
  17. Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT. The SF 36 health survey questionnaire: an outcome measure suitable for routine use within the NHS?. BMJ. 1993;306:1440–1444
  18. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118:622–629
  19. Wiebe S, Guyatt GH, Weaver B, Matijevic S, Sidwell C. Comparative responsiveness of generic and specific quality of life instruments. J Clin Epidemiol. 2003;56:52–60
  20. Cronin L, Guyatt GH, Griffith L, Wong E, Azziz R, Futterweit W, et al. Development of a health related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab. 1998;83:1976–1987
  21. Kirshner B, Guyatt GH. A methodologic framework for assessing health indices. J Chronic Dis. 1985;38:27–36
  22. Guyatt GH, Bombardier C, Tugwell PX. Measuring disease-specific quality of life in clinical trials. CMAJ. 1986;134:889–895
  23. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86:1626–1632
  24. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology and management. Am J Obstet Gynecol. 1981;140:815–830
  25. Hines G, Moran C, Huerta R, Folgman K, Azziz R. Facial and abdominal hair growth in hirsutism: a computerized evaluation. J Am Acad Dermatol. 2001;45:846–850
  26. Nunnally JC, Bernstein IH. Psychometric theory. 3rd edition. New York: McGraw-Hill; 1994;
  27. Bland JM, Altman DG. Statistics notes: Cronbach's alpha. BMJ. 1997;314:572
  28. Howell DC. Statistical methods for psychology. 4th edition. Boston, MA: Duxbury Press; 1997;p. 596
  29. Azziz R, Ehrmann DA, Legro RS, Whitcomb R, Hanley R, Fereshetian AG, et al. Authors' response: troglitazone use in polycystic ovary syndrome. [Letter] J Clin Endocrinol Metab. 2001;86:5090–5091
  30. Streiner DL, Norman G. Health measurement scales: a practical guide to their development and use. 2nd edition. Oxford: Oxford University Press; 1995;
  31. Norman GR, Streiner DL. Biostatistics: the bare essentials. 2nd edition. Hamilton, Ontario: B.C. Decker; 2000;p. 173
  32. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407–415
  33. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol. 1994;47:81–87
  34. Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol. 1996;98:843–845
  35. Redelmeier DA, Goldstein RS, Guyatt GH. Assessing the minimal important difference in symptoms: a comparison of techniques. J Clin Epidemiol. 1996;49:1215–1219

PII: S0895-4356(04)00162-3

doi: 10.1016/j.jclinepi.2003.10.018

Journal of Clinical Epidemiology
Volume 57, Issue 12 , Pages 1279-1287 , December 2004

Article Tools